HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Serum Krebs von den Lungen-6 levels in psoriatic patients under treatment with biologics

Files in This Item:
J Dermatol_KL-6 in psoriasis with biologics.pdf1.02 MBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Serum Krebs von den Lungen-6 levels in psoriatic patients under treatment with biologics
Authors: Iwata, Hiroaki Browse this author →KAKEN DB
Haga, Naoya Browse this author
Sugai, Tatsuro Browse this author
Fujita, Yasuyuki Browse this author
Keywords: biologics
Krebs von den Lungen‐6
tumor necrosis factor‐α
Issue Date: Mar-2021
Publisher: John Wiley & Sons
Journal Title: Journal of dermatology
Volume: 48
Issue: 3
Start Page: 376
End Page: 379
Publisher DOI: 10.1111/1346-8138.15665
Abstract: During biologic treatments, attention should be paid to adverse reactions, particularly infectious diseases. Furthermore, drug-induced interstitial lung disease is also known to be associated with biologic therapies. We retrospectively reviewed serum Krebs von den Lungen-6 (KL-6) levels in psoriatic patients who underwent treatment with seven different biologics. A total of 67 patients who received 80 biologic treatments were evaluated. The 31 anti-tumor necrosis factor (TNF)-alpha treatments consisted of 17 infliximab (IFX) and 14 adalimumab. The 23 anti-interleukin (IL)-23 treatments consisted of 14 ustekinumab and nine guselkumab. The 26 anti-IL-17 treatments consisted of nine secukinumab, six ixekizumab and 11 brodalumab. The IFX showed significantly increased mean serum KL-6 (170.9%), but none of the other treatments showed significant increases. Thirteen of the 17 (75.6%) patients in the IFX and 17 of the 31 (54.8%) patients in the total anti-TNF-alpha group demonstrated at least a 25% increase in serum KL-6. Levels exceeding the cut-off (500 U/mL) were detected in three patients before treatment and in seven patients after treatment. This study showed that anti-IL-17 and anti-IL-23 treatments have no significant impact on serum KL-6 level. In addition to the influence of IFX, a significantly large number of patients in the IFX group had a history of methotrexate administration associated with psoriatic arthritis, which might have influenced the KL-6 level. None of the patients with elevated serum KL-6 showed pulmonary changes by computed tomography and/or X ray.
Rights: "This is the peer reviewed version of the following article: Iwata, H., Haga, N., Sugai, T. and Fujita, Y. (2021), Serum Krebs von den Lungen‐6 levels in psoriatic patients under treatment with biologics. J. Dermatol., 48: 376-379, which has been published in final form at This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions."
Type: article (author version)
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 岩田 浩明

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University